Diabetes doesn’t clock off at 5 p.m., and neither do its costs.
Every glucose check, clinic visit, or insulin refill carries both a financial and emotional weight, shared unequally between patients, providers, and payers. Behind every test strip, sensor, or prescription lies the same question: who pays — and why?

In 2025, diabetes reimbursement has become one of the most decisive forces shaping global diabetes care and the economics behind it. The rising diabetes cost burden—now consuming over 10–14% of national health budgets—means that payers are increasingly evaluating Continuous Glucose Monitoring (CGM) reimbursement, insulin pump reimbursement, and digital diabetes reimbursement through strict cost-effectiveness models. Countries across Europe and the US are shifting toward value-based diabetes care, linking reimbursement to outcomes such as HbA1c reduction and Time in Range (TIR). Understanding how diabetes is reimbursed in 2025 is critical to understanding who receives innovation, how systems control expenditure, and why reimbursement policy now drives clinical practice.

Today, more than 530 million people worldwide live with diabetes — a figure expected to reach 780 million by 2045. Managing this single disease already absorbs over 10% of total health expenditure in most developed economies. As prevalence rises and technologies evolve, reimbursement policy has become the true gatekeeper of innovation, determining which therapies, diagnostics, and digital tools reach the people who need them most.

The Rising Diabetes Cost Crisis: Why Reimbursement Decisions Matter in 2025

The economic weight of diabetes care is overwhelmingly driven by its complications — from cardiovascular disease and renal failure to amputations and hospital admissions. These events cost two to eleven times more to treat than diabetes itself.

Each episode of poor glycaemic control represents both a clinical setback and an economic loss. Limited access to innovative therapies, delays in reimbursement, and fragmented primary care amplify avoidable expenditure across health systems. In countries where adoption of new antidiabetic drugs or connected technologies lags, the absence of timely reimbursement often results in greater long-term fiscal pressure and preventable hospital costs.

The main cost drivers in diabetes care, and the reimbursement signals they send to payers, can be summarised as follows:

Cost driver	Impact on health systems	Reimbursement / policy signal
Complications (CV, renal, foot)	2–11× higher costs than uncomplicated diabetes care	Prioritise funding for CGM, pumps, and AID to prevent late-stage events
Hospital admissions & DKA	Up to ~70% of total diabetes expenditure in many systems	Reward technologies that reduce emergency visits and acute bed days
Poor Time in Range (TIR)	More hypoglycaemia, variability, and crisis-driven care	Link reimbursement to TIR and HbA1c outcomes (value-based contracts)
Low adherence due to co-pays	Therapy discontinuation and avoidable complications	Design reimbursement to minimise harmful cost-sharing for high-risk patients
Delayed adoption of proven tech	Long-term cost escalation despite short-term budget savings	Use conditional/early-access schemes for evidence-based innovations

Global Diabetes Devices and CGM Reimbursement Trends

Global diabetes device reimbursement market 2024-2029

The global diabetes-care device market is projected to reach $26.8 billion by 2029, expanding at an annual rate of about 10%. This growth is fuelled not only by the rising prevalence of diabetes but also by expanding reimbursement frameworks for connected and smart technologies—including continuous glucose monitoring (CGM) systems, insulin pumps, and hybrid closed-loop platforms.

Market leaders such as Abbott (Libre), Dexcom (G7), Medtronic (MiniMed 780G), Insulet (Omnipod 5), and Tandem (t:slim X2) continue to dominate reimbursement listings across the US and Europe. At the same time, smaller innovators in digital coaching, remote titration, and AI-assisted dosing are entering outpatient and community-care settings through new funding corridors such as Remote Patient Monitoring (RPM), PECAN (France), and NICE conditional approvals (UK).

As outpatient diabetes management becomes increasingly data-driven, reimbursable ecosystems that connect sensors, insulin delivery, and digital coaching are overtaking standalone devices, signalling a global shift toward value-based diabetes care

How Diabetes Reimbursement Works in 2025: A Country-by-Country Breakdown

France – Value-Based Digital Integration

France has become one of Europe’s most progressive markets for connected diabetes care through a blend of national reimbursement (LPPR) and regional digital-health pilots.

Under the PECAN programme (Parcours de Soins Connectés et Numériques), the Haute Autorité de Santé (HAS) and the Caisse Nationale d’Assurance Maladie (CNAM) jointly evaluate evidence from clinical, technical, and economic perspectives.

Continuous Glucose Monitoring (CGM) devices and insulin pumps are reimbursed through the LPPR list, primarily under codes 1180–1200, once the manufacturer demonstrates safety, cost-effectiveness, and measurable improvements in glycaemic outcomes.
Funding flows from CNAM to prescribers and suppliers as part of routine reimbursement; hospitals and ambulatory centres are paid per-device under the LPPR tariff, while patients face no direct charge beyond standard insurance contributions.
Digital coaching and remote-monitoring platforms may obtain temporary conditional funding under PECAN or Article 51 innovation frameworks, typically for 24–36 months, during which real-world evidence is collected to confirm clinical and economic value.

This results in a value-based reimbursement ecosystem: technologies that reduce complications, hospitalisations, or clinician workload are prioritised for permanent inclusion. By tying reimbursement to outcomes rather than volume, France is setting a model for evidence-linked payment in chronic disease management.

Germany – Bundled Care Under §140 SGB V

Germany operates one of Europe’s most structured yet adaptable reimbursement environments for diabetes technologies. More than 90 % of the population is insured under the Statutory Health Insurance (Gesetzliche Krankenversicherung, GKV), meaning that reimbursement is largely determined by national decision-making through the Gemeinsamer Bundesausschuss (G-BA) and executed by the regional sickness funds such as AOK, BARMER, and TK.

Continuous Glucose Monitoring (CGM) and insulin pump therapy are reimbursed as outpatient services under the Einheitlicher Bewertungsmaßstab (EBM) catalogue, using codes 01480–01488, once G-BA benefit evaluation confirms medical necessity and cost-effectiveness. Hospitals and endocrinology practices bill these codes directly to the sickness funds, ensuring full coverage for eligible patients.
Hybrid closed-loop systems (AID) can be prescribed for both Type 1 and selected Type 2 patients following individual assessment. Devices are typically financed via outpatient EBM tariffs, with consumables and software updates covered under negotiated supply contracts with sickness funds.
For digital diabetes therapeutics, Germany’s Digitale-Gesundheitsanwendungen (DiGA) framework provides a separate reimbursement pathway. After approval by the BfArM and demonstration of “positive healthcare effects,” diabetes apps for insulin titration, self-management, or behavioural change are fully reimbursed within the GKV and billed directly through pharmacies or physicians.
Several sickness funds, including AOK PLUS and BARMER, are piloting integrated-care contracts under § 140 SGB V, combining CGM, remote patient monitoring, and structured education. These outcome-based contracts reward documented improvement in HbA1c, time in range, or reduction in hospital admissions, rather than unit sales.

Together, these mechanisms position Germany as a front-runner in outcomes-based diabetes reimbursement, linking payer investment directly to real-world clinical performance and long-term cost containment.

🇫🇮 Finland – Lessons from Reimbursement Reform

Finland provides a compelling example of how reimbursement reform can reshape both patient behaviour and national healthcare expenditure. The Finnish Health Insurance Scheme (Kela) covers virtually all residents, and medicines are reimbursed according to a three-tier model administered by the Pharmaceutical Pricing Board (Hila):

Basic rate (40 %) for general prescription medicines,
Lower special rate (65 %) for chronic but manageable diseases,
Higher special rate (100%) for severe or replacement therapies such as insulin.

In January 2017, a major reform lowered reimbursement for non-insulin antidiabetic drugs—including GLP-1 analogues, DPP-4 inhibitors, and SGLT2 inhibitors—from the higher special rate (100%) to the lower special rate (65%). The policy objective was to reduce annual public expenditure on medicines by €150 million, with diabetes contributing roughly €26 million to that target.

The reform was designed under the assumption that newer antidiabetic agents, although clinically superior in weight and cardiovascular profiles, could be used more selectively without affecting overall glycaemic control. Policymakers expected that rational prescribing and lifestyle intervention would offset increased patient co-payments.

Evidence from national pharmacy and patient surveys later revealed a more nuanced outcome:

Approximately 47% of Finnish adults with type 2 diabetes reported being affected by the reform.
The most common consequences were economic strain (32%), annoyance (12%), and changes in medication behavior, including dosage reduction or temporary discontinuation.
Patients using GLP-1 analogues or SGLT2 inhibitors experienced an average annual copayment rise of €150–€300, while those on older oral agents saw only minor increases (~€12 per year).
Although national prescription statistics showed only a 1% decline in non-insulin antidiabetic consumption, qualitative data indicated poorer adherence among low-income and elderly groups—risking long-term deterioration in glycemic control and complication rates.

Finland’s experience demonstrates the bi-directional link between reimbursement and clinical outcomes. While short-term fiscal savings were achieved, the reform underscored that increased patient cost-sharing can erode medication adherence, potentially offsetting savings through higher rates of hospitalisation, cardiovascular events, and renal failure.

As a result, subsequent policy discussions within Kela and Hila have emphasised value-based reimbursement models, focusing on long-term outcome data and risk-adjusted co-payments rather than across-the-board reductions. Newer frameworks now promote real-world evidence (RWE) collection and post-market monitoring before revising reimbursement tiers—bringing Finland closer to the evidence-linked models seen in France and Germany.

Finland’s reform shows that pharmacoeconomic efficiency cannot be separated from behavioral science. In chronic conditions such as diabetes, reimbursement design must account for both elasticity of demand and patient capacity to adhere; otherwise, short-term savings can trigger long-term clinical and fiscal rebound.

United Kingdom – NICE and NHS Digital Expansion

The United Kingdom has undergone one of the most significant reimbursement expansions for diabetes technologies in Europe, driven by a combination of robust health-economic evidence and a commitment to value-based care within the National Health Service (NHS).

In March 2023, the National Institute for Health and Care Excellence (NICE) issued updated guidelines that extended Continuous Glucose Monitoring (CGM) access to all insulin-treated people with Type 2 diabetes, recognising strong evidence of cost-effectiveness at £16,000–£25,000 per QALY, well below the UK’s usual willingness-to-pay threshold of £30,000. The NICE analysis demonstrated that CGM use improves Time in Range (TIR), reduces severe hypoglycaemia, and cuts hospital admissions, ultimately reducing long-term costs associated with complications such as cardiovascular disease, renal failure, and amputations.

Following NICE’s endorsement, NHS England and Integrated Care Boards (ICBs) implemented nationwide funding through the Diabetes Best Practice Tariff (BPT), which now covers both CGM and structured education as part of a single integrated care pathway.

Hospitals and community clinics receive activity-based reimbursement for each eligible patient enrolled in structured diabetes management.
Device suppliers are reimbursed via central procurement frameworks under the NHS Supply Chain, ensuring national price consistency.
Patients incur no direct cost, with supplies distributed through hospital diabetes teams or accredited community providers.

The BPT incentivises high-quality, guideline-compliant care by rewarding providers for achieving process and outcome indicators—such as documented TIR improvement, HbA1c reduction, and completion of structured education programmes like DAFNE (Dose Adjustment for Normal Eating) and DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed).

Beyond CGM, hybrid closed-loop (AID) systems are currently undergoing real-world evaluation under the NHS Innovation Accelerator and MedTech Funding Mandate, which provide early adoption and reimbursement support for technologies with proven clinical and economic benefit. Early trials have shown a 10–15% increase in TIR and improved patient satisfaction without additional cost burden.

The UK model illustrates a mature evidence-to-reimbursement continuum, where health-economic evaluation directly informs coverage. By combining NICE appraisal, tariff-based incentives, and national procurement, the NHS ensures that cost-effective diabetes innovations are adopted rapidly and equitably.
Looking ahead, integrated-care systems are expected to expand reimbursement to real-time remote monitoring, digital coaching, and AI-assisted insulin titration, aligning with the NHS Long Term Plan’s objectives for personalised, data-driven chronic disease management.

🇺🇸 United States – Medicare and Remote Monitoring

Medicare covers CGM for all insulin users and reimburses data-driven diabetes management via CPT codes 95251, 99457 (RPM), and 99490 (CCM). Commercial insurers follow with value-based contracts tying payments to improved Time in Range (TIR), reduced HbA1c, and fewer ER visits.

The Economics Behind Coverage Decisions

Cost Driver	Impact on Payers	Policy Response
Hospitalisation for complications	Up to 70 % of total diabetes costs	Funding of CGM & AID to prevent crises
Delayed adoption of novel therapies	Rising long-term morbidity	Conditional reimbursement / early-access schemes
Fragmented data systems	Weak real-world evidence	Integration of device data into payer dashboards

Across Europe, cost-utility studies place insulin pumps and closed-loop systems within **€11 000–€45 000 per QALY**, comfortably below most national willingness-to-pay thresholds. Payers now recognise that every 1 % drop in HbA1c can save €30–40 million per year in avoided complications.

Digital Diabetes Care and Remote Monitoring

Modern diabetes management is rapidly evolving into a digitally connected ecosystem, where algorithms not only analyse glucose data but also interpret dietary patterns, sleep quality, physical activity, and stress metrics to individualise care. These systems employ machine learning–driven insulin titration and predictive modelling to anticipate fluctuations before they occur — reducing variability, hypoglycaemia risk, and clinician workload.

Across major markets, these digital diabetes platforms are now reimbursable:

In the United States, coverage is enabled through Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) codes (CPT 99457, 99458, 99490, 95251), allowing healthcare providers to claim reimbursement for ongoing algorithm-supported management outside clinic visits.
In Germany, certified DiGA (Digitale Gesundheitsanwendungen) apps for diabetes self-management, CGM integration, and insulin dosing are fully reimbursed within the Statutory Health Insurance (GKV) system after BfArM validation.
In France, the PECAN framework supports conditional funding for digital coaching and telemonitoring programmes, linking reimbursement to reductions in emergency visits and improvement in HbA1c and Time in Range (TIR).
Within the NHS (UK), similar data-driven models are being tested through the Innovation Accelerator and Best Practice Tariff extensions for virtual diabetes reviews.

The next phase is outcome-linked reimbursement, where payment is tied to sustained glycaemic improvement, reduced acute-care utilisation, or long-term complication avoidance. This transition from fee-for-service to value-based digital healthcare positions data analytics and continuous monitoring as both clinical tools and economic levers — transforming diabetes from a reactive cost centre into a predictive, precision-managed condition.

Who Pays for Innovation?

Public payers fund devices proven to cut hospital stays or emergencies.
Private insurers adopt outcomes-based contracts and tiered co pay models.
Employers and wellness networks co-fund pre-diabetes platforms integrating CGM with coaching and nutrition support.
Patients increasingly access micro-reimbursement or subscription models for digital diabetes care.

Key Numbers at a Glance

Complications cost 2–11× more than uncomplicated care.
CGM coverage now exists in 45+ countries.
Hybrid closed-loop systems improve time in range by 10–15%.
Each 1% reduction in HbA1c can save €30 million annually in national health budgets.

How Odelle Technology Helps

Odelle Technology supports innovators, payers and policymakers in turning clinical data into reimbursable value:

Coding & tariff mapping across LPPR, EBM, CCSD, CPT frameworks
Health-economic modelling – Budget Impact (BIA), Cost-Utility (CUA), Cost-Consequence (CCM)
Real-World Evidence (RWE) design for connected devices & digital therapeutics
Payer engagement with CNAM, HAS, IQWiG, NICE, Kela and CMS
Market access strategy tailored for EU, UK and US systems

By linking economic evidence to real clinical outcomes, Odelle Technology helps transform diabetes care from cost centre to a value driver.

Glossary of Key Terms

CGM – Continuous Glucose Monitoring
CSII – Continuous Subcutaneous Insulin Infusion
HCL/AID – Hybrid Closed-Loop/Automated Insulin Delivery
QALY – Quality-Adjusted Life Year, a standard health-economic measure
ICER – Incremental Cost-Effectiveness Ratio (ΔCost ÷ ΔQALY)
PECAN – French fast-track scheme for connected health reimbursement
RPM / CCM – Remote Patient Monitoring / Chronic Care Management codes (US Medicare)

FAQs – Diabetes Reimbursement Explained

Which countries reimburse continuous glucose monitors?

Over 45 countries now cover CGM devices for insulin-treated diabetes. France, Germany, Sweden, and the UK include CGM under public insurance, while Medicare and most US commercial plans also reimburse them.

Are insulin pumps covered for type 2 diabetes?

Coverage for T2D is expanding: the Netherlands, Finland and the UK reimburse pumps for intensively insulin-treated T2D patients when cost-effective thresholds are met.

Which countries reimburse continuous glucose monitors (CGMs)?

Over 45 countries now reimburse Continuous Glucose Monitoring (CGM) systems for insulin-treated diabetes.
France, Germany, Sweden, and the UK provide public insurance coverage through national tariffs, while the United States covers CGM for all insulin users via Medicare and major commercial plans.
Reimbursement decisions are based on evidence of improved Time in Range (TIR), reduced hypoglycaemia events, and demonstrated cost-effectiveness in national health-economic models.

Are insulin pumps covered for type 2 diabetes?

Coverage for type 2 diabetes (T2D) is expanding rapidly.

The Netherlands, Finland, and the UK reimburse insulin pumps for intensively insulin-treated T2D when cost-effectiveness thresholds (typically €20 000–€45 000 per QALY) are met.
In Germany, eligibility can be approved by the G-BA following specialist review.
Clinical studies show that insulin-pump therapy improves glycaemic stability and reduces hospital admissions, supporting its inclusion in reimbursement schedules across Europe and the US.

How are digital diabetes apps reimbursed?

Digital diabetes therapeutics — such as insulin-titration or lifestyle-coaching apps — are reimbursed through evidence-based national frameworks:

🇩🇪 Germany’s DiGA reimburses CE-marked apps after BfArM approval and proven real-world outcomes.
🇫🇷 France’s PECAN allows conditional reimbursement for 24–36 months pending clinical validation.
🇬🇧 The NHS supports digital apps via NICE evaluation, the Innovation Accelerator, and the Best Practice Tariff (BPT).
🇺🇸 CMS RPM and CCM codes (CPT 99457, 99458, 99490) pay providers for continuous digital monitoring and patient engagement.
Each model links payment to measurable outcomes, not app downloads.

What is the cost-effectiveness threshold for diabetes technologies?

Most European health systems assess cost-effectiveness using incremental cost-effectiveness ratios (ICERs) expressed as cost per quality-adjusted life year (QALY) gained.

UK (NICE): £20 000–£30 000 per QALY
France (HAS): €30 000–€50 000 per QALY (context-specific)
Germany (IQWiG): Case-by-case efficiency-frontier analysis
Technologies such as CGM and hybrid closed-loop systems generally fall below these thresholds, supporting wide reimbursement.

How are remote monitoring and telediabetes services paid for?

Remote monitoring is reimbursed through a mix of procedure codes and outcome-based contracts:

US: RPM (CPT 99457/99458) and CCM (99490) allow monthly billing for continuous data review.
France: Telemonitoring is covered under PECAN pilots.
Germany: Remote data review is reimbursed via EBM 01480–01488 and selective contracts under § 140 SGB V.
UK: Virtual-care models are funded through ICB-commissioned pathways and NHS Innovation Accelerator pilots.
Reimbursement levels depend on evidence that virtual monitoring reduces acute-care utilisation and improves glycaemic outcomes.

Who evaluates whether a diabetes technology is reimbursable?

Each country has a dedicated Health Technology Assessment (HTA) body that reviews clinical and economic evidence:

NICE (UK)
HAS (France)
G-BA / IQWiG (Germany)
Kela / Hila (Finland)
CMS / AHRQ (United States)
Assessment focuses on clinical benefit, safety, real-world evidence, and budget impact before national listing or tariff inclusion.

How do value-based contracts work for diabetes care?

Value-based contracts tie payment to achieved health outcomes — for example, sustained HbA1c improvement, increased time in range, or reduced hospital admissions.
Payers such as AOK (Germany), CNAM (France), and Medicare (US) are piloting agreements where device makers or digital-health providers share financial risk if expected outcomes are not met.
These models align reimbursement with long-term population health and cost-containment goals.

Do private insurers pay for digital diabetes care?

Yes. In both Europe and the US, private insurers are adopting outcome-based reimbursement for digital therapeutics.

In the UK, major private providers reference CCSD codes for structured digital diabetes programmes.
In Germany, supplementary insurers co-fund DiGA apps beyond statutory coverage.
In the US, self-insured employers and payers like UnitedHealthcare and Cigna run performance-based contracts, linking payment to improved HbA1c or lower emergency-department use.

Why does real-world evidence matter for reimbursement?

Regulators and payers now demand proof that diabetes technologies deliver benefits outside clinical trials. Real-world evidence (RWE) — collected through registries, claims data, and connected devices — demonstrates durability, safety, and economic impact.
Schemes like PECAN (France) and DiGA (Germany) require RWE to move from temporary to permanent listing, while NICE and CMS increasingly reference post-market RWE in coverage decisions.

What is Value-Based Reimbursement?

Value-based reimbursement (VBR) is a healthcare payment model that rewards providers, payers, and technology developers for achieving measurable health outcomes rather than the number of consultations or devices supplied.

In diabetes and digital health, this means that reimbursement is linked to metrics such as improved Time in Range (TIR), reduction in HbA1c, fewer hospitalisations, and better patient-reported outcomes. When these targets are met, payers reimburse at higher rates or extend national coverage.

In the United States, RPM and CCM codes (CPT 99457, 99458, 99490) enable payment for ongoing data-driven monitoring; outcome-based contracts tie revenue to clinical improvement.
In Germany, DiGA apps are listed and reimbursed only if they deliver proven positive healthcare effects verified by real-world evidence.
In France, PECAN pilots link conditional funding to quantifiable reductions in acute-care costs.
Within the NHS (UK), the Best Practice Tariff (BPT) incentivises structured education and CGM use that demonstrate better outcomes for people with diabetes.

By aligning payment with verified benefit, value-based reimbursement transforms digital diabetes care into a data-driven partnership between innovators and payers, ensuring that technologies are financed not for their novelty, but for their proven ability to improve lives and reduce long-term healthcare expenditure.

How do digital diabetes apps get paid?

Digital diabetes therapeutics—covering glucose tracking, insulin titration, and behavioural coaching—are increasingly being recognised as reimbursable medical interventions rather than wellness tools. The mechanisms vary by country, but all rely on clinical evidence and demonstrable health-economic value.

🇩🇪 Germany
Germany leads the world with its DiGA (Digitale Gesundheitsanwendungen) framework. Once an app is approved by the Federal Institute for Drugs and Medical Devices (BfArM), it is added to the DiGA Directory for temporary national reimbursement under the Statutory Health Insurance (GKV). Manufacturers must show positive healthcare effects—such as improved HbA1c, Time in Range (TIR), or adherence—within 12 months through real-world data (RWD) collection to secure permanent listing. Physicians prescribe DiGA apps via e-prescription, and sickness funds pay developers directly at regulated tariffs.
🇫🇷 France
France reimburses digital diabetes tools under the PECAN (Parcours de Soins Connectés et Numériques) programme, co-managed by the Haute Autorité de Santé (HAS) and CNAM. Eligible digital therapeutics receive conditional national coverage for 24–36 months, during which clinical outcomes, usability, and cost-effectiveness are monitored in real-world settings. Upon positive evaluation, they can transition to LPPR permanent reimbursement. Examples include CGM-linked coaching platforms and telemonitoring apps for insulin titration and self-management.
🇬🇧 United Kingdom
In the UK, digital diabetes apps can gain reimbursement through multiple channels:
- NICE Digital Health Technologies Framework – evaluation for evidence, cost-effectiveness, and cybersecurity compliance.
- NHS Innovation Accelerator and MedTech Funding Mandate – early adoption and national procurement for cost-saving technologies.
- Integration into the Best Practice Tariff (BPT) for diabetes management, where structured education and remote monitoring are funded together.
  Approved apps are procured centrally via NHS Supply Chain or regionally through Integrated Care Boards (ICBs).
🇺🇸 United States
In the US, digital diabetes therapeutics are reimbursed through a mix of Medicare, Medicaid, and commercial payer pathways.
- Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) codes (CPT 99457, 99458, 99490, 95251) allow physicians to bill for remote glucose review, algorithmic insulin adjustment, and digital coaching.
- Category III CPT codes (e.g., 0704T–0712T) are used for emerging AI-driven digital therapeutics.
- Payers such as UnitedHealthcare and Anthem are piloting outcomes-based contracts, where payment depends on reduced HbA1c or lower hospitalisation rates.
  Some digital therapeutics are also pursuing FDA De Novo or Breakthrough Device designations to strengthen reimbursement positioning.
🇳🇴 Nordics (Finland, Sweden, Denmark)
Nordic countries are integrating digital diabetes apps through national innovation pilots and real-world reimbursement experiments, often linked to value-based procurement and outcome-based pricing. In Finland, Kela supports temporary funding under research programmes aligned with the Nordic Digital Health Network; in Sweden, regional health authorities can reimburse CE-marked digital therapeutics under the Vision eHealth 2030 framework once health-economic benefit is proven.

In all systems, reimbursement depends on the same triad: clinical efficacy, real-world evidence (RWE), and economic impact. Digital diabetes therapeutics that demonstrate measurable reductions in acute-care utilisation, improved adherence, or sustained glycaemic stability are the ones gaining coverage first — redefining how digital health becomes a reimbursed standard of care rather than a consumer add-on.

What evidence do payers require for diabetes reimbursement and digital diabetes reimbursement?

For diabetes reimbursement — including CGM reimbursement, insulin pump reimbursement, and digital diabetes reimbursement — payers require robust clinical, safety, and economic evidence that technologies deliver measurable value.

Health Technology Assessment (HTA) bodies such as NICE (UK), HAS (France), IQWiG / G-BA (Germany), Kela / Hila (Finland), and CMS / AHRQ (US) demand a combination of:

Clinical effectiveness data — showing improved HbA1c, Time in Range (TIR), and fewer hypoglycaemia events.
Health-economic models — demonstrating positive Incremental Cost-Effectiveness Ratios (ICERs) and budget impact, typically below £30 000 or €45 000 per Quality-Adjusted Life Year (QALY).
Real-world evidence (RWE) is collected through digital platforms, registries, and remote patient monitoring (RPM) programmes.

For digital diabetes therapeutics reimbursement, additional requirements include usability validation, data privacy compliance, and long-term adherence metrics. Under frameworks like Germany’s DiGA and France’s PECAN, digital diabetes tools must demonstrate both clinical efficacy and economic benefit during conditional funding periods to achieve permanent reimbursement listing.

Ultimately, payers link diabetes reimbursement to proven outcomes: lower complication rates, reduced hospitalisation, and improved patient engagement. Without high-quality evidence, even innovative digital diabetes tools cannot secure reimbursement.

How long does it take for a new diabetes technology or digital diabetes app to achieve reimbursement approval?

The diabetes reimbursement timeline — whether for continuous glucose monitors (CGM), insulin pumps, or digital diabetes apps — varies by country and evidence pathway.

Germany (DiGA): A digital diabetes app can reach temporary reimbursement within 6–12 months after BfArM approval, followed by a 12-month data collection phase to demonstrate real-world benefit for permanent reimbursement.
France (PECAN): Conditional funding for diabetes technologies lasts 24–36 months, during which real-world data on clinical outcomes and economic savings must be submitted to HAS and CNAM for full inclusion on the LPPR reimbursement list.
United Kingdom (NICE / NHS England): Traditional medical devices such as insulin pumps and CGM systems undergo a 12–18-month appraisal before inclusion in the NICE MedTech evaluation and national funding through the Best Practice Tariff (BPT).
United States (CMS / FDA): For digital diabetes therapeutics, gaining reimbursement via Remote Patient Monitoring (RPM) or Chronic Care Management (CCM) codes can take 6–9 months post-FDA clearance, though broader Medicare coverage determinations may extend to 18–24 months.
Nordic countries (Kela, Sweden’s Vision eHealth 2030): Reimbursement pilots for digital diabetes care usually last 12–24 months, linking public funding to outcome-based procurement.

Across all systems, faster diabetes reimbursement approval depends on clinical validation, cost-effectiveness analysis, and alignment with national value-based healthcare priorities. Companies that integrate real-world evidence generation early in their strategy — a core focus of Odelle Technology — are positioned to achieve digital diabetes reimbursement more efficiently.

Closing Insight

Diabetes care is shifting from fragmented fee-for-service treatment toward integrated, outcome-driven ecosystems. By rewarding prevention and real-world impact, reimbursement policies are quietly reshaping the future of metabolic health. Those who connect scientific evidence to payer value will define the next era of diabetes innovation.

Contact Odelle Technology
📧 steven@odelletechnology.com
🌐 www.odelletechnology.com

What Drives the Global Economics of Diabetes Care in 2025?

Diabetes now consumes over 10–14% of national health budgets in most OECD economies.
The economic burden is driven less by routine care than by micro- and macrovascular complications—including renal failure, myocardial infarction, stroke, neuropathy, and limb amputation. Each event increases annual cost by 2–11×.
Recent cost-of-illness studies show that for every 1% improvement in HbA1c, population-level healthcare costs decline by €30–40 million annually due to reduced hospitalisation and dialysis rates.
As a result, reimbursement strategies increasingly prioritise preventive, digital, and data-driven technologies that maintain glycaemic stability and avert costly crises.

Why Is Continuous Glucose Monitoring (CGM) a Cost-Saving Intervention?

CGM has transitioned from a luxury to a cost-saving standard of care.
Health-economic analyses across Europe and the US show ICER values between €11 000–€45 000 per QALY, well below typical national thresholds (HAS €50 000; NICE £30 000).
By improving Time in Range (TIR) and reducing severe hypoglycaemia, CGM prevents emergency admissions and productivity loss.
For example, France’s HAS found that widespread CGM adoption could avert 25,000 acute admissions annually, yielding net savings within 18 months of reimbursement rollout.

How Do Value-Based Reimbursement Models Work for Diabetes Technologies?

Value-based reimbursement (VBR) shifts payments from volume to verified outcomes.
Under Germany’s §140 SGB V and France’s Article 51/PECAN pilots, reimbursement is tied to reduction in HbA1c, hospital days, or clinician workload.
If defined outcomes are not met, manufacturers may face rebates or price renegotiation.
These mechanisms convert clinical endpoints into economic KPIs—ensuring that payer investment tracks measurable population health gain.

What Is the ICER Threshold for Diabetes Devices Across Europe?

Thresholds vary but converge on value:

Country	Threshold	Notes
🇬🇧 UK (NICE)	£20 000–£30 000 / QALY	Standard for MedTech cost-utility
🇫🇷 France (HAS)	€30 000–€50 000 / QALY	Context-specific, lower for chronic disease
🇩🇪 Germany (IQWiG)	Efficiency frontier	No fixed number; comparative benefit
🇫🇮 Finland (Hila)	€25 000–€40 000 / QALY	Used in recent drug appraisals

Most CGM, insulin pump, and hybrid closed-loop systems fall comfortably within these ranges, supporting sustained reimbursement.

How Is Real-World Evidence (RWE) Changing Diabetes Reimbursement?

RWE now determines whether temporary reimbursement becomes permanent.
Under PECAN (France), DiGA (Germany), and NHS Innovation Accelerator (UK), post-market data on HbA1c, TIR, and hospitalisation rates must confirm trial findings.
Manufacturers use device telemetry, claims data, and registries to provide longitudinal outcome evidence.
Payers reward those who demonstrate real-world durability—a key determinant of tariff retention and price stability.

Why Did Finland’s 2017 Reimbursement Reform Become a Global Case Study?

Finland reduced coverage of modern non-insulin antidiabetic drugs from 100 % to 65 %, saving €150 million short-term but causing adherence decline and inequity.
Follow-up studies revealed a 47% patient impact rate and increased discontinuation among low-income groups.
The lesson: fiscal cuts without behavioural modelling backfire. Subsequent reforms restored selective full reimbursement and linked copayments to real-world outcomes—one of the earliest value-based pharmacy models in Europe.

How Do Remote Patient Monitoring (RPM) Codes Support Diabetes Care in the US?

US Medicare covers continuous data review under CPT 95251, 99457, 99458, and 99490.
These allow billing for:

CGM data interpretation (95251)
Remote physiological monitoring (99457–99458)
Chronic care management (99490)

Clinicians earn $54–$121 per month per patient, incentivising digital follow-up.
Commercial payers mirror this via value-based contracts linking reimbursement to TIR improvement or ER-visit reduction.

What Is PECAN, and Why Is France’s Model Unique?

PECAN (Parcours de Soins Connectés et Numériques) is France’s flagship digital-health funding programme.
It grants 24–36 months of conditional reimbursement to connected care tools—CGM-linked coaching, telemonitoring, or insulin-titration apps—while real-world outcomes are collected.
HAS and CNAM co-evaluate clinical, technical, and economic data before permanent LPPR listing.
This makes PECAN a hybrid between reimbursement and pragmatic clinical trial, accelerating innovation while safeguarding payer value.

How Does Germany’s DiGA Framework Apply to Diabetes Apps?

Germany’s Digitale Gesundheitsanwendungen (DiGA) fast-track allows CE-marked digital therapeutics to gain temporary reimbursement under the Statutory Health Insurance (GKV).
To maintain listing, the app must prove positive healthcare effects within 12 months—typically a ≥0.5% HbA1c reduction or 10% TIR increase.
Physicians prescribe via e-prescription; payers pay developers directly.
This evidence-linked model has inspired similar frameworks in France (PECAN) and the Nordics.

How Does the NHS Combine NICE Appraisal and Reimbursement?

NICE evaluates cost-effectiveness; NHS England implements via Best Practice Tariff (BPT) or Innovation Mandate.
CGM, AID, and digital coaching are reimbursed when below £30 000/QALY and demonstrably improve outcomes.
ICBs fund structured education and monitoring as a single pathway—rewarding completion and HbA1c improvement.
This integration converts NICE guidance into automatic reimbursement at scale, reducing regional inequity.

What Are Hybrid Closed-Loop (HCL) Systems and How Are They Funded?

HCL, or Automated Insulin Delivery (AID) systems, combine CGM with algorithmic pumps.
Clinical trials show a 10–15% increase in time in range, and a 0.5–0.7% HbA1c reduction.
France (LPPR code 1180+), Germany (EBM 01480–01488), and the UK (BPT pilot) reimburse under existing pump tariffs with outcome monitoring.
Given cost-effectiveness ratios < €30 000/QALY, HCL is expected to become the next global standard of reimbursed diabetes care.

What Role Does Behavioural Economics Play in Diabetes Reimbursement Design?

Reimbursement elasticity matters.
When co-payments rise, adherence falls non-linearly—especially in chronic diseases with “silent symptoms.”
Behavioural-economics modelling (price elasticity ≈ –0.25 to –0.4) helps policymakers set optimal cost-sharing that maintains adherence while ensuring fiscal sustainability.
Finland’s 2017 reform failure and France’s PECAN design both reflect behavioural sensitivity to cost signals.

How Do Payers Use Real-World Data (RWD) for Diabetes Outcomes Tracking?

Payers integrate RWD through claims analytics, EHR integration, and device telemetry.
KPIs include:

% patients achieving HbA1c < 7%
Mean TIR increase ≥ 10 %
Hospital admissions per 1000 diabetics
Medication adherence rates

Dashboards link these outcomes to payment bonuses or contract renewals.
This data-driven contracting transforms reimbursement into a live feedback system.

What Are the Top Reimbursed Digital Diabetes Therapeutics in Europe?

mySugr (Roche) – DiGA-listed self-management app (Germany)
ESYSTA (Emperra) – Bluetooth insulin pen with data portal
Insulia (Voluntis) – PECAN pilot for insulin titration (France)
Hedia Diabetes Assistant – Danish-developed, CE-marked coaching app now under PECAN and DiGA review
These apps share one trait: documented real-world outcomes and data-interoperability with CGM systems.

How Do Employers and Private Insurers Fund Digital Diabetes Care?

Employers integrate CGM + coaching subscriptions into corporate wellness programmes.
US firms using Omada Health or Virta Health report ROI > 2:1 through reduced absenteeism and hospitalisation.
In the UK, Bupa and AXA PPP use CCSD codes to fund remote diabetic care within private insurance frameworks.
Outcome-based bonuses encourage adherence, aligning private payers with value-based principles.

What Is the Future of Outcome-Linked Diabetes Reimbursement?

Next-generation models use dynamic pricing—tariffs that decrease as marginal benefit declines or increase with sustained outcome improvement.
AI-enabled analytics allow risk-adjusted payments based on patient complexity.
By 2030, outcome-linked reimbursement will integrate biomarker, behavioural, and economic indicators, forming self-learning payer systems.

How Do HTA Agencies Evaluate Diabetes Technologies?

HTA bodies assess four evidence pillars:

Clinical effectiveness – RCTs & RWE on HbA1c, TIR, adverse events
Safety – Device accuracy, hypoglycaemia risk, cybersecurity
Economic evaluation – CUA/BIA/ICER relative to standard of care
Societal impact – QoL, productivity, equity
NICE, HAS, IQWiG, and Kela apply adapted GRADE or efficiency-frontier methodologies to ensure decisions reflect both clinical and fiscal realism.

Why Is Time in Range (TIR) Emerging as a Reimbursement Metric?

TIR better reflects day-to-day glycaemic control than HbA1c alone.
Every 10% TIR increase equates to a 0.8% HbA1c reduction and fewer hospitalisations.
Hence, France’s PECAN and Germany’s §140 SGB V contracts now link reimbursement to documented TIR gains, making it a currency of value-based diabetes care.

What Are the Health-Economic Returns of Preventing a Single Hospitalisation?

A single avoided diabetic ketoacidosis (DKA) or severe hypoglycaemia admission saves €3 000–€8 000 in direct cost and ~€1 500 in productivity loss.
Scaling prevention via CGM or AID across 100 000 patients yields annual savings exceeding €500 million.
Such quantifiable ROI is what transforms pilot projects into permanent reimbursement.

How Does Odelle Technology Turn Clinical Evidence into Reimbursable Value?

Odelle Technology bridges science, economics, and policy by:

Mapping reimbursement codes (LPPR, EBM, CCSD, CPT)
Building Budget-Impact and Cost-Utility Models (BIA/CUA)
Designing RWE frameworks that align with HAS, IQWiG, NICE, Kela, and CMS
Facilitating payer dialogues and value-based contracting

This integrated evidence approach converts clinical performance into tariff inclusion, accelerating access and sustainability for diabetes innovations worldwide.

Reference List for “The New Rules of Diabetes Reimbursement”

A curated collection of authoritative international sources across HTA, reimbursement, economic modelling, CGM, AID, DiGA, PECAN, NICE, Medicare and digital therapeutics.

1. Global Diabetes Burden & Economics

International Diabetes Federation (IDF) – Diabetes Atlas, 10th Edition (2021)

Link: https://idf.org/diabetesatlas
Description:
Global gold-standard data on diabetes prevalence, projections to 2045, regional trends, and economic burden. Source of the 530M→780M numbers and a key reference for any serious discussion of global diabetes epidemiology and macro-level cost pressure.

World Health Organization – Global Report on Diabetes

Link: https://www.who.int/publications/i/item/global-report-on-diabetes
Description:
High-level synthesis on mortality, morbidity, risk factors, and health-system impact of diabetes. Explains how complications such as cardiovascular disease and kidney failure drive escalating costs and why early control is now framed as an economic rather than purely clinical priority.

OECD – Health at a Glance (Diabetes & Chronic Disease Expenditure Sections)

Link: https://www.oecd.org/health/health-at-a-glance/
Description:
Comparative data across OECD countries on healthcare spending, including the share attributable to diabetes and other chronic diseases. Useful for underpinning the statement that diabetes consumes 10–14% of health budgets and for benchmarking national performance.

2. Cost-of-Illness & Complications

American Diabetes Association – Economic Costs of Diabetes in the U.S.

Link: https://diabetesjournals.org/care
Description:
Landmark cost-of-illness analyses quantifying the direct medical costs, lost productivity, and societal impact of diabetes in the United States. Provides concrete numbers for hospitalisation costs, DKA, hypoglycaemia, and long-term complications, illustrating the “2–11× higher cost” message.

European Cost-of-Illness Studies for Diabetes (Multiple Countries)

Link: https://pubmed.ncbi.nlm.nih.gov/?term=diabetes+cost+europe
Description:
Cluster of peer-reviewed national studies assessing the economic burden of diabetes in France, Germany, the UK, Nordics, and others. These papers support statements on how every 1% HbA1c improvement translates into tens of millions of euros saved at population level.

3. Continuous Glucose Monitoring (CGM) & Hybrid Closed-Loop (AID)

NICE Guideline NG28 & Related Technology Appraisals (CGM in T1D & T2D)

Link: https://www.nice.org.uk/guidance/ng28
Description:
UK national guidance that expanded CGM eligibility to all insulin-treated Type 2 diabetes patients. Includes detailed economic modelling showing ICERs typically below £25,000/QALY and robust evidence for improved Time in Range (TIR), fewer severe hypos, and reduced admissions.

Haute Autorité de Santé (HAS) – Freestyle Libre / CGM Evaluation

Link: https://www.has-sante.fr
Description:
French HTA evaluations of FreeStyle Libre and other CGM systems, including clinical benefit ratings and conditions for LPPR listing. Supports your claims about LPPR reimbursement, cost-effectiveness expectations, and the French preference for technologies that prevent late-stage complications.

IQWiG / G-BA Diabetes Technology Assessments (Germany)

Link: https://www.iqwig.de/en/projects-results/projects/diabetes-care.html
Description:
German assessments of CGM, pump therapy, and related technologies using the efficiency-frontier approach. Forms the technical basis for G-BA benefit decisions and confirms that German payers require demonstrable outcomes rather than simple “me too” add-ons.

American Diabetes Association – Standards of Medical Care in Diabetes (Annual)

Link: https://diabetesjournals.org/care/issue
Description:
Authoritative clinical guidelines summarising evidence for CGM, CSII pumps, and hybrid closed-loop systems in T1D and T2D. Widely cited in HTA dossiers and payer submissions to support claims on HbA1c reduction, TIR improvements, and hypoglycaemia risk mitigation.

4. France – PECAN, LPPR, CNAM, Article 51

HAS – Evaluation Framework for Digital Medical Devices & Telemonitoring (PECAN)

Link: https://www.has-sante.fr
Description:
Methodological framework describing how France evaluates connected care and digital therapeutics under PECAN. Outlines clinical, technical, cybersecurity, and economic criteria—exactly the rulebook for digital diabetes tools looking for conditional reimbursement.

LPPR (Liste des Produits et Prestations Remboursables) – Official Device List

Link: https://www.ameli.fr/accueil-de-la-donnees/open-data-lpp/index.php
Description:
Open data repository of reimbursed medical devices in France, including CGM sensors, insulin pumps, and consumables. The key reference for LPPR codes and tariffs (e.g., your 1180–1200 mention) and proof that a device has moved from “pilot” to fully reimbursed.

CNAM – Article 51 Innovation Schemes & Care-Pathway Reform

Link: https://www.cnam.fr
Description:
Documentation on experimental payment models and integrated-care pilots that sit alongside PECAN. Provides context for Article 51 funding and how France uses temporary, controlled roll-outs to evaluate new diabetes and telemonitoring models before national adoption.

5. Germany – G-BA, IQWiG, EBM, §140 SGB V, DiGA

Gemeinsamer Bundesausschuss (G-BA) – Diabetes Technology Decisions

Link: https://www.g-ba.de/beschluesse/
Description:
Central repository of benefit decisions that determine what is funded under Statutory Health Insurance (GKV). This is the ultimate arbiter for CGM, insulin pumps, and AID in Germany, and the reference behind your statement that nothing reaches patients without G-BA approval.

EBM (Einheitlicher Bewertungsmaßstab) – Outpatient Tariff Catalogue

Link: https://www.kbv.de/html/ebm.php
Description:
Official coding and tariff catalogue for outpatient services, including CGM data interpretation and pump management (e.g., 01480–01488). This is where you anchor your comments about how endocrinologists and diabetologists bill sickness funds for digital and device-supported care.

DiGA Directory – Reimbursed Digital Health Applications

Link: https://diga.bfarm.de/de/verzeichnis
Description:
Germany’s live directory of all approved and reimbursed digital health applications. Lists diabetes apps and insulin-titration tools that have demonstrated “positive healthcare effects” in real-world use, making it the primary evidence that digital therapeutics can achieve national reimbursement.

IQWiG – Methods & Efficiency Frontier Guidance

Link: https://www.iqwig.de/en/methods.3027.html
Description:
Detailed methodology documents explaining how IQWiG conducts economic evaluations and uses the efficiency-frontier concept instead of a single ICER threshold. Ideal citation for explaining why Germany “has no fixed number” but still operates within an implicit cost-effectiveness logic.

§140 SGB V Integrated-Care Contracts (Selective Contracts)

Link: https://www.gkv-spitzenverband.de
Description:
Legal and policy background for integrated-care and disease-management contracts in Germany. Provides the foundation for your discussion of outcome-based diabetes contracts combining CGM, education, and remote monitoring.

6. Finland – Kela, Hila & the 2017 Reimbursement Reform

Kela – Finnish Health Insurance Scheme, Medicine Reimbursement Rules

Link: https://www.kela.fi/web/en/medicines-reimbursement
Description:
Explains how pharmaceutical reimbursements are structured into basic and special rates, including for antidiabetic drugs. Core reference for your three-tier 40% / 65% / 100% explanation and for understanding patient copay shifts.

Hila – Pharmaceutical Pricing Board Decisions & Methodology

Link: https://www.hila.fi
Description:
Official body that sets reimbursable prices and reimbursement categories. Relevant for anchoring the discussion on how Finland reclassified GLP-1, DPP-4 and SGLT2 therapies and what motivated the targeted €150M annual savings.

Finnish Studies on the 2017 Antidiabetic Reimbursement Change

Link: https://pubmed.ncbi.nlm.nih.gov
Description:
Empirical analyses of how the 2017 reforms affected adherence, out-of-pocket spending, and perceived financial strain among people with Type 2 diabetes. These are the evidence base for your “47% affected” and “€150–€300 copayment rise” statements, and for the behavioural-economics framing.

7. United Kingdom – NICE, NHS England, BPT & Innovation

NICE – Technology Appraisals and Guidelines for Diabetes Devices

Link: https://www.nice.org.uk/guidance
Description:
Portfolio of guidance documents covering insulin pumps, CGM systems, and digital tools in Type 1 and Type 2 diabetes. Provides the official ICER ranges, QALY thresholds, and clinical-effectiveness conclusions that underpin UK reimbursement decisions.

NHS England – Diabetes Best Practice Tariff (BPT)

Link: https://www.england.nhs.uk
Description:
Describes how hospitals and community providers are paid for delivering high-quality integrated diabetes care, including structured education and CGM. This is the key document for your statements on linking tariff payments to education completion, TIR, and HbA1c outcomes.

NHS Innovation Accelerator & MedTech Funding Mandate

Link: https://nhsaccelerator.com
Description:
National acceleration programmes that support early adoption of cost-saving technologies such as hybrid closed-loop systems and virtual diabetes services. Evidence that the NHS is willing to fund promising innovations ahead of universal tariff updates when economic benefit is clear.

8. United States – CMS, Medicare, RPM/CCM & Digital Therapeutics

CMS – Remote Patient Monitoring and Chronic Care Management Codes

Link: https://www.cms.gov/medicare
Description:
Official policy and billing guidance for CPT codes 95251, 99457, 99458, 99490 and related RPM/CCM codes. Core reference for how U.S. providers are paid monthly for interpreting CGM data and remotely managing people with diabetes.

FDA – Digital Health Center of Excellence

Link: https://www.fda.gov/medical-devices/digital-health
Description:
Provides regulatory context for software-as-a-medical-device, AI-driven diabetes tools, and digital therapeutics. Useful to show that U.S. reimbursement for digital diabetes care is underpinned by a maturing regulatory framework rather than ad-hoc exceptions.

AHRQ – Evidence Reports on Diabetes Management and Quality Improvement

Link: https://www.ahrq.gov
Description:
Systematic reviews and technology assessments on diabetes interventions, care models, and safety. These documents feed into payer and CMS decision-making, and can be cited to support claims about the evidence base for CGM and RPM-supported care.

9. Behavioural Economics & Adherence

Health Affairs – Studies on Cost-Sharing and Medication Adherence

Link: https://www.healthaffairs.org
Description:
Peer-reviewed analyses quantifying how changes in copayments affect adherence to chronic-disease medications. Support your use of price elasticity ranges (–0.25 to –0.4) and underline the behavioural risk of raising cost-sharing in conditions like diabetes.

BMJ / JAMA / Other Journals – Impact of Cost-Sharing on Diabetes Control

Link: https://www.bmj.com / https://jamanetwork.com
Description:
High-quality papers linking increased out-of-pocket costs to poorer glycaemic control, treatment discontinuation, and higher rates of emergency care. These make the Finland case study feel less anecdotal and more aligned with global evidence.

10. Digital Diabetes Therapeutics – DiGA, PECAN, NHS, Nordics

DiGA Directory – Digital Health Apps with Proven Healthcare Benefits

Link: https://diga.bfarm.de/de/verzeichnis
Description:
Lists all apps approved for reimbursement in Germany, including diabetes self-management tools and insulin titration apps. Demonstrates that digital therapeutics can be prescribed like drugs and paid for nationally when they show real-world outcome gains.

Voluntis – Insulia Insulin Titration Companion

Link: https://voluntis.com
Description:
An example of a digital insulin-titration solution evaluated under European frameworks such as PECAN and DiGA. Useful as a concrete illustration of how dosing algorithms, CGM integration, and coaching are combined into reimbursed digital care.

mySugr – Roche Digital Diabetes Companion

Link: https://mysugr.com
Description:
Widely used self-management app that integrates with CGM and glucose meters, and has been part of German and other European reimbursement discussions. Helps ground your list of “top reimbursed digital diabetes therapeutics” with a recognisable brand.

Nordic Digital Health / Vision eHealth 2030 (Sweden)

Link: https://www.government.se / regional eHealth portals
Description:
National and regional frameworks in Sweden, Finland, and Denmark for integrating digital therapeutics and remote care into publicly funded pathways. Provide context for your comments on outcome-based procurement and pilot-based reimbursement for digital diabetes tools in the Nordics.

11. Health-Economic Methodology & HTA

ISPOR – Guidelines for Economic Evaluations in Diabetes and Chronic Disease

Link: https://www.ispor.org
Description:
International methodological guidance on cost-utility analysis, budget-impact analysis, and modelling choices for chronic diseases. These documents sit behind many of the ICER and QALY thresholds quoted by HTA agencies and reinforce your methodological credibility.

CHEERS 2022 – Consolidated Health Economic Evaluation Reporting Standards

Link: https://www.ispor.org/cheers
Description:
Updated reporting checklist for economic evaluations, endorsed globally. Referencing CHEERS signals that your discussion of ICERs, QALYs, and model transparency aligns with current best practice.

National HTA Agencies – Methodology Pages

NICE (UK): https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
HAS (France): https://www.has-sante.fr/jcms/r_1499257/en/economic-evaluation
IQWiG (Germany): https://www.iqwig.de/en/methods.3027.html
Kela / Hila (Finland): https://www.hila.fi

Description:
Each agency’s formal description of how they appraise technologies, weigh uncertainty, and interpret cost-effectiveness. These pages are perfect backlinks for your sections on ICER thresholds and the different philosophical approaches taken by HTA bodies.